Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioCryst nets $29.9mm in private placement

Executive Summary

BioCryst Pharmaceuticals (enzyme blockers for cancer and cardiovascular, autoimmune, and infectious diseases) netted $29.9mm through the private placement of 2.2mm common shares priced at $13.46 each (a 9% discount to market). Institutional investors included Kleiner Perkins Caufield & Byers and Texas Pacific Group Ventures.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies